about
Can Invalid Bioactives Undermine Natural Product-Based Drug Discovery?A brief review of recent Charcot-Marie-Tooth research and prioritiesIn silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feedingNatural-product-derived fragments for fragment-based ligand discoveryRational methods for the selection of diverse screening compoundsUnderstanding and classifying metabolite space and metabolite-likenessCapturing nature's diversityTemplate CoMFA Generates Single 3D-QSAR Models that, for Twelve of Twelve Biological Targets, Predict All ChEMBL-Tabulated AffinitiesCapture and exploration of sample quality data to inform and improve the management of a screening collection.Design, synthesis and spectroscopic characterisation of a focused library based on the polyandrocarpamine natural product scaffold.Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.Synthesis of an azide-tagged library of 2,3-dihydro-4-quinolones.Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective.Structure-based discovery of A2A adenosine receptor ligands.Challenges of antibacterial discoveryIncreased diversity of libraries from libraries: chemoinformatic analysis of bis-diazacyclic libraries.Solid-phase synthesis and chemical space analysis of a 190-membered alkaloid/terpenoid-like libraryRecent trends and observations in the design of high-quality screening collections.Characterizing the diversity and biological relevance of the MLPCN assay manifold and screening set.The rise, fall and reinvention of combinatorial chemistry.Composition and applications of focus libraries to phenotypic assaysTowards the systematic exploration of chemical space.Design and synthesis of screening libraries based on the muurolane natural product scaffold.Diversity-oriented synthesis: producing chemical tools for dissecting biology.Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptorDruggable chemical space and enumerative combinatorics.The importance of molecular complexity in the design of screening libraries.Structural diversity of biologically interesting datasets: a scaffold analysis approach.Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.Structural dynamics and inhibitor searching for Wnt-4 protein using comparative computational studies.Chemical informatics and target identification in a zebrafish phenotypic screen.Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.Cheminformatic comparison of approved drugs from natural product versus synthetic origins.Synthetic analogs of stryphnusin isolated from the marine sponge Stryphnus fortis inhibit acetylcholinesterase with no effect on muscle function or neuromuscular transmission.Biofocussed chemoprospecting: An efficient approach for drug discovery.Asymmetric synthesis of vinylogous β-amino acids and their incorporation into mixed backbone oligomers.Genomes to natural products PRediction Informatics for Secondary Metabolomes (PRISM)CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites.Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern.Docking and chemoinformatic screens for new ligands and targets.
P2860
Q26778522-80D1CBB2-BEE5-48CA-AB57-D1C9C803FC52Q27012700-5261D09D-43D0-40B8-A81E-7A1E4CFF7C49Q27316596-DC694BE6-1E90-40C5-AC20-064BAC8EE931Q27683610-4DD9C429-3104-4E84-BD5E-C88EE30DFD37Q28303907-22F97A62-2DB0-4F3A-B429-74E4D1E6AC5AQ28478426-B8491E2A-872F-443E-8C01-667D2805C381Q28546640-3866B036-DB73-49C5-BE5D-EEFB96A83A25Q28648497-D614F0E8-C5EE-4E4C-B655-4099ACE6F776Q30663371-AD2F9660-18E0-45C9-9195-E77E662B7A00Q31115817-030E2016-F530-43D9-B4CA-B255E017337FQ31139520-FD8E0FC2-1E2C-4F33-85D6-45A98B8F2A4CQ33530207-A83ADCB9-1ECB-429E-836F-F21A67756675Q33536938-53ED02D0-6D70-466F-A1F7-6DB36AC65525Q33560239-F378AD92-7943-4A2D-A5C2-6AE930A30C9DQ33793074-EDEB036B-B465-4A66-928A-139F32299435Q33812015-6303DA4F-88E5-48FC-ACFB-29C2DEBCD00EQ33857987-A3343399-0185-49C3-8528-C0F1F0676413Q33893113-B599AA26-FEBF-4125-AA10-C71F1A784A32Q33898089-4B84E8D3-FB50-4D13-9CB8-6DDC0850BF4BQ33942110-DF7EF50E-B20F-4020-8371-866486E5E9C9Q33944326-81955A4B-62E8-4060-AA16-2FC1CBBAD4FAQ34039203-CD3FA8C9-81E6-431B-978B-85007CD53D84Q34197608-3D20E317-A67D-4FB2-8B20-59D713FBADC4Q34227440-30F01262-DCD1-470A-AD7E-4A9FF349A3A4Q34619309-1431D75F-D82F-4723-9839-4803681FD573Q34675477-68560C03-9448-499F-A7F5-3794F577C743Q35016524-F2FE3431-BBF6-40BD-AC6F-737E42946260Q35231290-FAE4DCE1-3888-47BB-8B95-75699E2FA09FQ35549895-5027155B-D71D-4CE6-B823-1693232F1069Q35586235-E9B8D4CB-CE21-4706-AE2C-FB01064D9F94Q35683136-EDE075E3-CD32-4DC3-BA7D-DB7805A5AB20Q36083075-204E1CEB-47A7-4A16-BF71-FBA70F05D18EQ36167128-69061B64-37C5-4BAB-96AA-C18D23B616E9Q36191540-8C75F7D3-AE95-41AE-832B-FAA03B1A1EF0Q36264598-1AD6D0FD-3A71-414E-8DE1-3AD19AB89C78Q36324082-A18C6D45-4311-4EC4-8434-1FCA451474F8Q36676569-1680CD9A-57A0-4506-8F02-8FB0C9D59E2AQ36693185-A123DE74-3C14-4D55-A631-76C2CF851561Q37139471-3ED6E067-BB7F-4F9F-B66F-BC90724C684BQ37592631-02AF5DEC-1B1E-4D25-AB71-06BCEDBE3084
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Quantifying biogenic bias in screening libraries.
@ast
Quantifying biogenic bias in screening libraries.
@en
type
label
Quantifying biogenic bias in screening libraries.
@ast
Quantifying biogenic bias in screening libraries.
@en
prefLabel
Quantifying biogenic bias in screening libraries.
@ast
Quantifying biogenic bias in screening libraries.
@en
P2860
P50
P356
P1476
Quantifying biogenic bias in screening libraries.
@en
P2093
Christian Laggner
Jérôme Hert
P2860
P2888
P304
P356
10.1038/NCHEMBIO.180
P577
2009-05-31T00:00:00Z